BACKGROUND: Patients with psoriasis show a greater prevalence of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than their counterparts with NAFLD and without psoriasis. The link between these three pathological conditions is a chronic low-grade inflammatory status. In this study, we aimed to evaluate the effect of etanercept versus psoralen and UVA (PUVA) therapy on the hepatic fibrosis risk in patients with psoriasis, metabolic syndrome, and NAFLD (with NAFLD diagnosed by ultrasonography). METHODS: Eighty-nine patients with chronic moderate-to-severe plaque-type psoriasis, metabolic syndrome, and NAFLD received etanercept or PUVA treatment. The two groups of patients were compared for anthropometric variables (body mass index and waist/hip ratio), lipid profile, glucose homeostasis, inflammatory status, risk of hepatic fibrosis, and ultrasonographic aspect of the liver, both at baseline (time [T] 0) and after 24 weeks of treatment (T24). RESULTS: After 24 weeks of treatment, only in the group receiving etanercept, we detected significant reductions (p < 0.05) in the aspartate transaminase (AST)/alanine transaminase (ALT) ratio, C-reactive protein (CRP) serum levels, fasting insulin levels, and homeostasis model assessment (HOMA) index, and a significant increase in the Quantitative Insulin-Sensitivity Check Index (QUICKI) (p < 0.05). CONCLUSIONS: In patients with psoriasis, metabolic syndrome, and NAFLD, the risk of the development of hepatic fibrosis seems to be directly correlated with insulin resistance. Etanercept could be more efficacious to reduce the risk of developing hepatic fibrosis than PUVA therapy, and this preventive effect could be related to its anti-inflammatory and glucose homeostatic properties. We note that a limitation of the study was that the diagnosis of NAFLD was conducted by ultrasonography.
BACKGROUND:Patients with psoriasis show a greater prevalence of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than their counterparts with NAFLD and without psoriasis. The link between these three pathological conditions is a chronic low-grade inflammatory status. In this study, we aimed to evaluate the effect of etanercept versus psoralen and UVA (PUVA) therapy on the hepatic fibrosis risk in patients with psoriasis, metabolic syndrome, and NAFLD (with NAFLD diagnosed by ultrasonography). METHODS: Eighty-nine patients with chronic moderate-to-severe plaque-type psoriasis, metabolic syndrome, and NAFLD received etanercept or PUVA treatment. The two groups of patients were compared for anthropometric variables (body mass index and waist/hip ratio), lipid profile, glucose homeostasis, inflammatory status, risk of hepatic fibrosis, and ultrasonographic aspect of the liver, both at baseline (time [T] 0) and after 24 weeks of treatment (T24). RESULTS: After 24 weeks of treatment, only in the group receiving etanercept, we detected significant reductions (p < 0.05) in the aspartate transaminase (AST)/alanine transaminase (ALT) ratio, C-reactive protein (CRP) serum levels, fasting insulin levels, and homeostasis model assessment (HOMA) index, and a significant increase in the Quantitative Insulin-Sensitivity Check Index (QUICKI) (p < 0.05). CONCLUSIONS: In patients with psoriasis, metabolic syndrome, and NAFLD, the risk of the development of hepatic fibrosis seems to be directly correlated with insulin resistance. Etanercept could be more efficacious to reduce the risk of developing hepatic fibrosis than PUVA therapy, and this preventive effect could be related to its anti-inflammatory and glucose homeostatic properties. We note that a limitation of the study was that the diagnosis of NAFLD was conducted by ultrasonography.
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand Journal: Lancet Date: 2005-11-05 Impact factor: 79.321
Authors: Gleison Vieira Duarte; Maria de Fatima S P Oliveira; Thiago M Cardoso; Ivonise Follador; Thadeu S Silva; Carolina M A Cavalheiro; Walker Nonato; Edgar M Carvalho Journal: Int J Dermatol Date: 2012-09-24 Impact factor: 2.736
Authors: Luca Miele; Selenia Vallone; Consuelo Cefalo; Giuseppe La Torre; Carmine Di Stasi; Fabio M Vecchio; Magda D'Agostino; Maria L Gabrieli; Vittoria Vero; Marco Biolato; Maurizio Pompili; Giovanni Gasbarrini; Gianludovico Rapaccini; Pierluigi Amerio; Clara De Simone; Antonio Grieco Journal: J Hepatol Date: 2009-06-26 Impact factor: 25.083
Authors: Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day Journal: Hepatology Date: 2007-04 Impact factor: 17.425
Authors: M Marra; A Campanati; R Testa; C Sirolla; A R Bonfigli; C Franceschi; F Marchegiani; A Offidani Journal: Int J Immunopathol Pharmacol Date: 2007 Oct-Dec Impact factor: 3.219
Authors: Fernanda Bu Pulzi; Raul Cisternas; Murilo R Melo; Cristiane Mf Ribeiro; Carlos A Malheiros; João E Salles Journal: Diabetol Metab Syndr Date: 2011-02-23 Impact factor: 3.320
Authors: A Campanati; P Neri; K Giuliodori; I Arapi; G Carbonari; E Borioni; C P Herbort; C Mariotti; A Giovannini; A Offidani Journal: Int Ophthalmol Date: 2014-05-06 Impact factor: 2.031
Authors: Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson Journal: Am J Physiol Endocrinol Metab Date: 2018-03-06 Impact factor: 4.310
Authors: Elisabeth K Malle; Nathan W Zammit; Stacey N Walters; Yen Chin Koay; Jianmin Wu; Bernice M Tan; Jeanette E Villanueva; Robert Brink; Tom Loudovaris; James Cantley; Shelli R McAlpine; Daniel Hesselson; Shane T Grey Journal: J Exp Med Date: 2015-06-29 Impact factor: 14.307
Authors: Jay Luther; John J Garber; Hamed Khalili; Maneesh Dave; Shyam Sundhar Bale; Rohit Jindal; Daniel L Motola; Sanjana Luther; Stefan Bohr; Soung Won Jeoung; Vikram Deshpande; Gurminder Singh; Jerrold R Turner; Martin L Yarmush; Raymond T Chung; Suraj J Patel Journal: Cell Mol Gastroenterol Hepatol Date: 2015-03